Idiopathic Thrombocytopenic Purpura (ITP) Clinical Trial
Official title:
The Clinical Trial of PG2 in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
This was a phase II multi-center, randomized, open-label study with two parallel study groups to evaluate the efficacy and safety of PG2 in ITP patients.
The primary objective of this exploratory study is to evaluate the efficacy of PG2 in raising the platelet counts in ITP patients using two dosing schedules. The secondary objective is to determine the safety of PG2 treatment among these patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01437384 -
Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.
|
Phase 1 | |
| Completed |
NCT01713738 -
Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
|
Phase 1/Phase 2 | |
| Completed |
NCT00362349 -
Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients
|
Phase 3 | |
| Withdrawn |
NCT00161564 -
A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone
|
Phase 2 | |
| Terminated |
NCT00571467 -
Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP
|
Phase 1 |